Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) - Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Assembly Biosciences in a research note issued on Monday, March 24th. HC Wainwright analyst E. Arce anticipates that the biopharmaceutical company will post earnings of ($12.58) per share for the year. HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Assembly Biosciences' current full-year earnings is ($6.87) per share.
A number of other equities analysts also recently commented on ASMB. Guggenheim assumed coverage on shares of Assembly Biosciences in a research note on Tuesday. They issued a "buy" rating and a $31.00 target price on the stock. StockNews.com downgraded shares of Assembly Biosciences from a "buy" rating to a "hold" rating in a research report on Monday, March 24th.
Check Out Our Latest Report on Assembly Biosciences
Assembly Biosciences Stock Down 2.6 %
Shares of NASDAQ:ASMB traded down $0.28 during midday trading on Tuesday, reaching $10.62. The company's stock had a trading volume of 12,009 shares, compared to its average volume of 24,885. The firm has a market cap of $79.68 million, a price-to-earnings ratio of -1.58 and a beta of 0.62. The business has a 50 day moving average price of $12.55 and a 200 day moving average price of $14.94. Assembly Biosciences has a 1 year low of $10.27 and a 1 year high of $19.93.
Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) EPS for the quarter, topping the consensus estimate of ($1.75) by $0.18. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%. The business had revenue of $7.36 million for the quarter, compared to analyst estimates of $7.05 million.
Insider Transactions at Assembly Biosciences
In other Assembly Biosciences news, Director Michael Houghton purchased 3,202 shares of the stock in a transaction dated Monday, December 30th. The shares were bought at an average cost of $15.61 per share, with a total value of $49,983.22. Following the completion of the transaction, the director now owns 3,202 shares in the company, valued at $49,983.22. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.10% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Assembly Biosciences
Several hedge funds have recently made changes to their positions in ASMB. FMR LLC raised its stake in shares of Assembly Biosciences by 29.7% in the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company's stock valued at $240,000 after acquiring an additional 3,635 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Assembly Biosciences by 5,137.3% in the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 3,442 shares during the period. Peapod Lane Capital LLC acquired a new stake in shares of Assembly Biosciences in the 4th quarter valued at approximately $994,000. Palumbo Wealth Management LLC acquired a new stake in Assembly Biosciences in the fourth quarter worth $180,000. Finally, Monimus Capital Management LP bought a new stake in shares of Assembly Biosciences in the 4th quarter valued at $664,000. Institutional investors own 19.92% of the company's stock.
About Assembly Biosciences
(
Get Free Report)
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Read More
Before you consider Assembly Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.
While Assembly Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
